Mainz Biomed N.V. received regulatory approval from Swissmedic in Switzerland on August 13, 2025, allowing ColoAlert® to be marketed in select European countries.
2 reports, 1 independent
Updated Aug 13
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Mainz Biomed N.V. received regulatory approval from Swissmedic in Switzerland on August 13, 2025, allowing ColoAlert® to be marketed in select European countries.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Switzerland
country in Central Europe
-
Swissmedic
licensing and inspection authority for remedies in Switzerland with headquarters in Bern
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireMainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert® BERKELEY, Calif. and MAINZ, Germany, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Com
- GlobeNewswireMainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition Company Advances its Progress toward FD